Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Rinzimetostat + Darolutamide in mCRPC (Himalayas-1)
NCT07723248Phase 3Recruiting
- Sponsor
- ORIC Pharmaceuticals
- Start
- Aug 2026
- Primary completion
- Mar 2028
- Countries
- 2
01
Overview
A Phase 3 trial of rinzimetostat in metastatic castration-resistant prostate cancer (mCRPC), sponsored by ORIC Pharmaceuticals. Started Aug 2026; status: recruiting.
02
Drugs
rinzimetostat
03
Conditions
metastatic castration-resistant prostate cancer (mCRPC)
Beyond the preview
Go deeper on NCT07723248.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT07723248.